FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896916898> ?p ?o ?g. }

• W2896916898 endingPage "266" @default.
• W2896916898 startingPage "259" @default.
• W2896916898 abstract "ObjectivesOne third of infrainguinal vein bypasses may fail within the first 1.5 years. Pro- and anti-inflammatory mechanisms are thought to be involved in these graft stenoses and occlusions. In previous studies, low levels of anti-phosphorylcholine IgM (anti-PC IgM, an innate anti-inflammatory IgM) have been associated with increased cardiovascular events. In this study, the peri-operative dynamics of anti-PC IgM levels were established during leg bypass surgery, and associations assessed between anti-PC IgM levels and primary graft patency.Design and methodsThis was a prospective, observational cohort study of infrainguinal autogenous vein bypass for peripheral arterial occlusive disease involving four university affiliated hospitals. Plasma cytokine and anti-PC IgM levels were measured pre- and post-operatively. The outcome of interest was loss of primary graft patency because of occlusion or intervention for graft stenosis.ResultsOne hundred and forty-two consecutive patients were enrolled: mean age 66 (46–91); 91% white race and male; 72.5% critical limb ischaemia (Fontaine III or IV). Median pre-operative anti-PC IgM levels were 49 units/mL (IQR 32.3–107.7, mean 89.8 + 101 sd). During follow up of an average of 1.8 years (1 month–7.4 years), 50 (35.2%) grafts lost primary patency. Pre-operative levels of interleukin 6 or C-reactive protein did not predict graft failure. Patients with pre-operative anti-PC IgM values in the lowest quartile had a twofold increased risk of graft failure (multivariable Cox proportional hazard, p = .03, HR 2.11, 95% CI 1.09–4.07), even after accounting for the other significant factors of conduit diameter, distal anastomosis, smoking, and the severity of leg ischaemia.ConclusionsLow levels of anti-PC IgM are associated with vein bypass graft failure. This biological mediator may be a useful marker to identify patients at higher risk, and offers the potential for novel, directed therapies for vascular inflammation and its consequences. One third of infrainguinal vein bypasses may fail within the first 1.5 years. Pro- and anti-inflammatory mechanisms are thought to be involved in these graft stenoses and occlusions. In previous studies, low levels of anti-phosphorylcholine IgM (anti-PC IgM, an innate anti-inflammatory IgM) have been associated with increased cardiovascular events. In this study, the peri-operative dynamics of anti-PC IgM levels were established during leg bypass surgery, and associations assessed between anti-PC IgM levels and primary graft patency. This was a prospective, observational cohort study of infrainguinal autogenous vein bypass for peripheral arterial occlusive disease involving four university affiliated hospitals. Plasma cytokine and anti-PC IgM levels were measured pre- and post-operatively. The outcome of interest was loss of primary graft patency because of occlusion or intervention for graft stenosis. One hundred and forty-two consecutive patients were enrolled: mean age 66 (46–91); 91% white race and male; 72.5% critical limb ischaemia (Fontaine III or IV). Median pre-operative anti-PC IgM levels were 49 units/mL (IQR 32.3–107.7, mean 89.8 + 101 sd). During follow up of an average of 1.8 years (1 month–7.4 years), 50 (35.2%) grafts lost primary patency. Pre-operative levels of interleukin 6 or C-reactive protein did not predict graft failure. Patients with pre-operative anti-PC IgM values in the lowest quartile had a twofold increased risk of graft failure (multivariable Cox proportional hazard, p = .03, HR 2.11, 95% CI 1.09–4.07), even after accounting for the other significant factors of conduit diameter, distal anastomosis, smoking, and the severity of leg ischaemia. Low levels of anti-PC IgM are associated with vein bypass graft failure. This biological mediator may be a useful marker to identify patients at higher risk, and offers the potential for novel, directed therapies for vascular inflammation and its consequences." @default.
• W2896916898 created "2018-10-26" @default.
• W2896916898 creator A5038648406 @default.
• W2896916898 creator A5044205142 @default.
• W2896916898 creator A5046957382 @default.
• W2896916898 creator A5047018613 @default.
• W2896916898 creator A5047827731 @default.
• W2896916898 creator A5052316265 @default.
• W2896916898 creator A5055826664 @default.
• W2896916898 creator A5064763862 @default.
• W2896916898 date "2019-02-01" @default.
• W2896916898 modified "2023-09-27" @default.
• W2896916898 title "Anti-phosphorylcholine IgM, an Anti-inflammatory Mediator, Predicts Peripheral Vein Graft Failure: A Prospective Observational Study" @default.
• W2896916898 cites W1968992062 @default.
• W2896916898 cites W1970918939 @default.
• W2896916898 cites W1971788185 @default.
• W2896916898 cites W1982413931 @default.
• W2896916898 cites W1983847379 @default.
• W2896916898 cites W1988140998 @default.
• W2896916898 cites W1988440326 @default.
• W2896916898 cites W1995631973 @default.
• W2896916898 cites W1996833096 @default.
• W2896916898 cites W2000227646 @default.
• W2896916898 cites W2007180943 @default.
• W2896916898 cites W2017357456 @default.
• W2896916898 cites W2040630327 @default.
• W2896916898 cites W2047101396 @default.
• W2896916898 cites W2047868136 @default.
• W2896916898 cites W2054736497 @default.
• W2896916898 cites W2057177438 @default.
• W2896916898 cites W2061804518 @default.
• W2896916898 cites W2090376073 @default.
• W2896916898 cites W2114447765 @default.
• W2896916898 cites W2116592902 @default.
• W2896916898 cites W2121645343 @default.
• W2896916898 cites W2125661827 @default.
• W2896916898 cites W2132326230 @default.
• W2896916898 cites W2134685432 @default.
• W2896916898 cites W2144118811 @default.
• W2896916898 cites W2159087408 @default.
• W2896916898 cites W2222331526 @default.
• W2896916898 cites W2311304902 @default.
• W2896916898 cites W2615504909 @default.
• W2896916898 cites W3144215568 @default.
• W2896916898 cites W4289886312 @default.
• W2896916898 cites W612043802 @default.
• W2896916898 cites W879143 @default.
• W2896916898 doi "https://doi.org/10.1016/j.ejvs.2018.09.010" @default.
• W2896916898 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7085348" @default.
• W2896916898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30343000" @default.
• W2896916898 hasPublicationYear "2019" @default.
• W2896916898 type Work @default.
• W2896916898 sameAs 2896916898 @default.
• W2896916898 citedByCount "5" @default.
• W2896916898 countsByYear W28969168982020 @default.
• W2896916898 countsByYear W28969168982022 @default.
• W2896916898 countsByYear W28969168982023 @default.
• W2896916898 crossrefType "journal-article" @default.
• W2896916898 hasAuthorship W2896916898A5038648406 @default.
• W2896916898 hasAuthorship W2896916898A5044205142 @default.
• W2896916898 hasAuthorship W2896916898A5046957382 @default.
• W2896916898 hasAuthorship W2896916898A5047018613 @default.
• W2896916898 hasAuthorship W2896916898A5047827731 @default.
• W2896916898 hasAuthorship W2896916898A5052316265 @default.
• W2896916898 hasAuthorship W2896916898A5055826664 @default.
• W2896916898 hasAuthorship W2896916898A5064763862 @default.
• W2896916898 hasBestOaLocation W28969168981 @default.
• W2896916898 hasConcept C126322002 @default.
• W2896916898 hasConcept C141071460 @default.
• W2896916898 hasConcept C188816634 @default.
• W2896916898 hasConcept C207103383 @default.
• W2896916898 hasConcept C2777202286 @default.
• W2896916898 hasConcept C2780007028 @default.
• W2896916898 hasConcept C44249647 @default.
• W2896916898 hasConcept C71924100 @default.
• W2896916898 hasConceptScore W2896916898C126322002 @default.
• W2896916898 hasConceptScore W2896916898C141071460 @default.
• W2896916898 hasConceptScore W2896916898C188816634 @default.
• W2896916898 hasConceptScore W2896916898C207103383 @default.
• W2896916898 hasConceptScore W2896916898C2777202286 @default.
• W2896916898 hasConceptScore W2896916898C2780007028 @default.
• W2896916898 hasConceptScore W2896916898C44249647 @default.
• W2896916898 hasConceptScore W2896916898C71924100 @default.
• W2896916898 hasFunder F4320332161 @default.
• W2896916898 hasFunder F4320337472 @default.
• W2896916898 hasIssue "2" @default.
• W2896916898 hasLocation W28969168981 @default.
• W2896916898 hasLocation W28969168982 @default.
• W2896916898 hasLocation W28969168983 @default.
• W2896916898 hasLocation W28969168984 @default.
• W2896916898 hasOpenAccess W2896916898 @default.
• W2896916898 hasPrimaryLocation W28969168981 @default.
• W2896916898 hasRelatedWork W1586374228 @default.
• W2896916898 hasRelatedWork W2003938723 @default.
• W2896916898 hasRelatedWork W2045240138 @default.
• W2896916898 hasRelatedWork W2047967234 @default.
• W2896916898 hasRelatedWork W2118496982 @default.
• W2896916898 hasRelatedWork W2364998975 @default.

• next